Blog
Cobolimab Biosimilar: Expanding Access to TIM-3 Immune Checkpoint Inhibition
Cobolimab is an investigational monoclonal antibody targeting T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), an immune checkpoint receptor implicated in T-cell exhaustion a
…
25th Nov 2024